PLEASANTON, Calif.--(BUSINESS WIRE)--
Industry comes together to advance product development and stay ahead of changing regulations
Veeva Systems (VEEV) will host the 2020 Medical Device & Diagnostics Summit June 1-2, 2020 in Minneapolis. Industry experts from the world’s most innovative medical device companies will share best practices to shorten the product development lifecycle and keep pace with evolving regulations such as MDR.
“Veeva is committed to helping the industry improve speed and agility across product development,” said Jim Diefenbach, general manager of medical device and diagnostics at Veeva. “We’re excited to bring the medical device and diagnostics community together to advance how the industry gets products to market and stays ahead of global compliance requirements.”
More than 70 medical device and diagnostics companies, including 8 of the 10 largest, now use applications from Veeva Vault Medical Device Suite. Attendees at Veeva Medical Device & Diagnostics Summit will discuss opportunities in commercial, clinical, quality, and regulatory to:
- Speed commercial content to market by combining digital asset management with review and distribution capabilities for end-to-end compliance.
- Streamline end-to-end clinical trial processes with unified applications for clinical operations and clinical data management to improve study visibility and performance.
- Seamlessly manage quality processes and content together for improved compliance and operational innovation.
- Unify regulatory information management to keep pace with changing regulations and growing complexity in product development.
Veeva Medical Device & Diagnostics Summit is complimentary for Veeva customers and invited guests. Pre-register at veeva.com/MedDeviceSummit.
Also, learn how Veeva is helping manufacturers improve speed and agility throughout the product development lifecycle at RAPS Regulatory Convergence in Philadelphia, Sept. 23-24, 2019 and the MedTech Conference in Boston, Sept. 23-25, 2019.
For more on Veeva Vault Medical Device Suite, visit: veeva.com/MedDevice
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veevasystems on Twitter: twitter.com/veevasystems
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 775 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com.
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended July 31, 2019. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.